Postprint

This is the accepted version of a paper published in *Clinical Biochemistry*. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Citation for the original published paper (version of record):

http://dx.doi.org/10.1016/j.clinbiochem.2012.09.022

Access to the published version may require subscription.

N.B. When citing this work, cite the original published paper.

Permanent link to this version:
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-182320
Day-to-day variation of urinary NGAL and rational for creatinine correction

Johanna Helmersson-Karlqvist*a, Johan Ärnlöv*b,c, Anders Larsson*a

*aDepartment of Medical Sciences/Clinical Chemistry, Uppsala University, Uppsala University Hospital, SE-751 85 Uppsala, Sweden; anders.larsson@akademiska.se

*bDepartment of Public Health and Caring Sciences/Geriatrics, Uppsala University, Uppsala Science Park, SE-751 85 Uppsala, Sweden; johan.arnlov@pubcare.uu.se

*cSchool of Health and Social Studies, Dalarna University, Falun, Sweden

*Corresponding author: Johanna Helmersson-Karlqvist, Department of Medical Sciences/Clinical Chemistry, Uppsala University Hospital, SE-75185 Uppsala, Sweden
Fax: +46-18-552562; Phone: +46-18-6114228
E-mail: Johanna.Helmersson_Karlqvist@medsci.uu.se
Abstract

Objectives: Clinical studies evaluating the new tubular biomarker urinary neutrophil gelatinase-associated lipocalin (U-NGAL) in urine increase and there is no consensus whether absolute U-NGAL concentrations or urinary NGAL/creatinine (U-NGAL/Cr) ratios should be used when chronic tubular dysfunction is studied. The aim was to study the biological variation of U-NGAL in healthy subjects and the rational for urinary Creatinine (U-Cr) correction in two different study samples.

Design and Methods: To study biological variation of U-NGAL and U-NGAL/Cr ratio and the association between U-NGAL and U-Cr in healthy subjects 13 young males and females (median age 29 years) collected morning urine in 10 consecutive days. Additionally, a random subsample of 400 males from a population-based cohort (aged 78 years) collecting 24-hour urine during one day was studied.

Results: The calculated biological variation for absolute U-NGAL was 27% and for U-NGAL/Cr ratio 101%. Absolute U-NGAL increased linearly with U-Cr concentration (the theoretical basis for creatinine adjustment) in the older males (R = 0.19, P<0.001) and with borderline significance in the young adults (R = 0.16, P = 0.08). The U-NGAL/Cr ratio was, however, negatively associated with creatinine in the older males (R = -0.14, P<0.01) and in the young adults (R = -0.16, P = 0.07) indicating a slight “overadjustment”.

Conclusions: The study provide some support for the use of U-NGAL/Cr ratio but the rather large biological variation and risk of possible overadjustment need to be considered. Both absolute U-NGAL and U-NGAL/Cr ratios should be reported for the estimation of chronic tubular dysfunction.

Keywords: biological variation, neutrophil gelatinase-associated lipocalin, tubular biomarker, creatinine ratio
Abbreviations: CV, coefficient of variation; U-Cr, urinary Creatinine, U-NGAL, urinary neutrophil gelatinase-associated lipocalin

1. Introduction

Neutrophil gelatinase-associated lipocalin (NGAL) [1], also known as human neutrophil lipocalin (HNL) [2] and lipocalin-2, is a member of the lipocalin family of binding proteins and is in the circulation mainly produced by activated neutrophils. The main source of urinary NGAL (U-NGAL) is however tubular epithelial cells in the kidney [3]. NGAL is produced and secreted into the urine in response to ischemic kidney damage and is therefore a promising early indicator of tubulointerstitial damage [4, 5]. Recent clinical studies show that U-NGAL reflect acute renal damage early [6-9] but may also signal chronic renal damage [10-13]. When mild to moderate increases in U-NGAL concentrations are expected it is of essence to know whether U-NGAL should be measured as absolute values or as a ratio to urinary Creatinine (U-Cr). There is no consensus how to best estimate U-NGAL in this sense. The aim of this study was to study the rational for U-Cr correction of U-NGAL using both young healthy subjects and a heterogeneous aged population and to study the biological day-to-day variation of U-NGAL in healthy subjects.

2. Patients and methods

To study the biological variation of U-NGAL and U-NGAL/Cr ratio and the associations between U-NGAL and U-Cr 13 young healthy male and female volunteers without medication (median age 29 years; interval 22-59 years) collected spot urine samples during ten successive days. The samples were collected in the morning (approximately 6-8 AM).
Additionally, to study the associations between U-NGAL and U-Cr in an older age-group a random subsample of 400 males, out of 839 males, collecting 24-hour urine during one day in the forth examination cycle of Uppsala Longitudinal Study of Adult Men (aged 77-78 years) [14] were examined. The samples were stored frozen at -70°C until analysis. The study has been cleared by the Ethics Review Board for human studies and patients have signed informed consent.

U-NGAL was analyzed with a commercial sandwich ELISA kit, (DY1757, R&D Systems, Minneapolis, MN). The method has a total coefficient of variation (CV) of 2.4 %. U-Cr was analysed with IL Test creatinine 181672-00 on a Monarch 2000 analyser, Instrumental Laboratories, Lexington, MA. The total CV for the U-Cr assay was 2.4 %.

U-NGAL and U-NGAL/Cr ratio was skewed according to Shapiro-Wilks test (W<0.95) and was log-transformed. Both U-NGAL and U-NGAL/Cr ratio showed W >0.95 (Shapiro-Wilks test) after transformation, thus assumed to be normally distributed. We used linear regression and Pearson’s correlation to study the linear associations between U-NGAL and U-NGAL/Cr ratio, respectively, and U-Cr in both study samples. To describe the biological variation of absolute U-NGAL and U-NGAL/Cr ratio in the healthy young subjects total CV (CV\text{tot}) was calculated from the root mean square error using ANOVA. Analytical CV (CV\text{ana}) for the NGAL method was calculated using multiple measurements of the same sample at different concentrations. CV\text{ana} for the U-NGAL/Cr ratio was estimated as the square root of the sum of the square of CV\text{ana} for the NGAL method and the square of CV\text{ana} for the U-Cr method. CV due to biological variation (CV\text{biol}) was estimated by the formula \( CV_{\text{tot}}^2 = CV_{\text{biol}}^2 + CV_{\text{ana}}^2 \). Calculations were performed with Stata 11.0 (College Station, TX).
3. Results

Median and interquartile interval of U-NGAL and U-NGAL/Cr ratio in morning urine during 10 successive days in the healthy young subjects are presented in Table 1. CV\textsubscript{tot} for U-NGAL was 27 % and CV\textsubscript{ana} 2.4 %, leading to a calculated CV\textsubscript{biol} of 27 %. CV\textsubscript{tot} for U-NGAL/Cr ratio was 101 % and CV\textsubscript{ana} 3.4 %, leading to a calculated CV\textsubscript{biol} of 101 %. Median and interquartile interval of U-NGAL and U-NGAL/Cr ratio in the population of aged males was 17.3 [10.0-30.8] μg/L and 2.0 [1.2-3.4] μg/mmol creatinine, respectively. As shown in Figure 1A and 2A, the concentrations of absolute U-NGAL increased with U-Cr concentration, as could be expected (the theoretical basis for creatinine adjustment). The Pearson correlation coefficient R between concentrations was 0.16 and borderline significant (p=0.08) for young healthy subjects and 0.19 (p<0.001) for the aged male population. However, expressing NGAL as a NGAL/Cr ratio caused a certain amount of ‘over-adjustment’ as could be seen as negative associations in Figure 1B and 2B. The correlation coefficient R was -0.16 and again borderline significant (p = 0.07) for young healthy subjects, but -0.14 and significant (p<0.01) for the aged male population.

4. Discussion

The positive linear associations between U-NGAL and U-Cr seen in both young, healthy subjects and in the older male subsample somewhat support the theoretical basis for creatinine adjustment. However, this study points out some important issues to consider. Firstly, the calculated biological variation of U-NGAL/Cr ratio was 101 % and thus considerably larger than the calculated biological variation of absolute U-NGAL which was only 27 %. The theoretical basis for U-Cr adjustment is to compensate for variations in urine concentrations (assuming a steady U-Cr excretion rate), thus reducing the variation of the biomarker. This study indicate however the opposite; a higher biological day-to-day variation in U-NGAL/Cr
ratio compared to absolute NGAL. The biological variation of the U-NGAL/Cr ratio is however at a similar level as in a recent study where the biological variation was estimated to 81 % for the U-NGAL/Cr ratio [15]. In the same study the biological variation of absolute U-NGAL was 84 % which is a considerably larger variation than in this study.

Secondly, it is important to bear in mind that adjustment with urinary creatinine may actually cause “overadjustment”, as seen in the negative correlations between the U-NGAL/Cr ratio and creatinine in this study. An overadjustment of creatinine may potentially impact associations and interpretation of results in clinical studies. Given the relatively week correlation between U-NGAL and U-Cr and the risk of overadjustment by creatinine as discussed above it is reasonable to suggest that laboratories should report both absolute U-NGAL and U-NGAL/Cr ratios for the estimation of chronic tubular dysfunction.

The study included apparently healthy subjects and participants from a community cohort who possible are healthier than the general population and the results of the study are not necessarily applicable to patients with specific diagnosis. Excretion of creatinine may vary with changes in glomerular filtration rate, thus the results may not be extrapolated to patients with acute kidney diseases [16]. To further evaluate the clinical importance and prognostic utility of U-NGAL versus U-NGAL/Cr ratio large prospective cohort studies are needed. In conclusion, this study provide some support for the use of U-NGAL/Cr ratio but the rather large biological variation and the risk of overadjustment must be taken into account when planning and interpreting a clinical study intended to study chronic tubular dysfunction.

Acknowledgements
We are grateful to Charina Brännström for skilled technical assistance. This work was supported by Uppsala-Örebro Regional Research Council (RFR), The Swedish Research Council (2006-6555), Swedish Heart-Lung foundation, and Dalarna University.

Conflict of interest

None.
References


Figure captions

Figure 1. Linear association between log U-NGAL and U-Cr in 13 healthy subjects during 10 successive days. (A) A borderline significant positive association between uncorrected U-NGAL and U-Cr; y = 2.68 + 0.04x, R = 0.16, P = 0.08. (B) After adjustment for creatinine, U-NGAL/Cr ratios are somewhat negatively associated with U-Cr; y = 1.33 -0.04x, R = -0.16, P = 0.07.

Figure 2. Linear association between log U-NGAL and U-Cr in 400 aged males during one single day. (A) A highly significant positive association between uncorrected U-NGAL and U-Cr; y = 9.13 + 0.07x, R = 0.19, P <0.001 was seen. (B) The U-NGAL/Cr ratio was negatively associated with U-Cr; y = 8.00 -0.05x, R = -0.14, P <0.01, indicating a possible “overadjustment”.
Table 1. Median concentrations (interquartile interval) of absolute U-NGAL, U-Cr and U-NGAL/Cr ratio in ten successive days in the 13 healthy subjects.

<table>
<thead>
<tr>
<th>Subject no.</th>
<th>U-NGAL (µg/L)</th>
<th>U-Cr (mmol/L)</th>
<th>U-NGAL/Cr ratio (µg/mmol creatinine)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>median 25-75 percentile</td>
<td>median 25-75 percentile</td>
<td>median 25-75 percentile</td>
</tr>
<tr>
<td>1</td>
<td>13 6.4-22</td>
<td>9.3 7.6-12</td>
<td>1.2 0.62-1.7</td>
</tr>
<tr>
<td>2</td>
<td>2.9 1.8-4.5</td>
<td>12 10-20</td>
<td>0.21 0.15-0.34</td>
</tr>
<tr>
<td>3</td>
<td>38 32-48</td>
<td>12 8.8-14</td>
<td>3.3 1.9-5.3</td>
</tr>
<tr>
<td>4</td>
<td>24 20-42</td>
<td>6.2 5.6-7.0</td>
<td>3.8 3.0-7.6</td>
</tr>
<tr>
<td>5</td>
<td>7.8 4.6-14</td>
<td>4.7 4.2-6.6</td>
<td>1.3 0.69-1.9</td>
</tr>
<tr>
<td>6</td>
<td>460 200-810</td>
<td>11 6.5-14</td>
<td>43 17-53</td>
</tr>
<tr>
<td>7</td>
<td>51 38-88</td>
<td>12 11-13</td>
<td>4.3 3.1-5.2</td>
</tr>
<tr>
<td>8</td>
<td>29 20-50</td>
<td>18 15-23</td>
<td>1.6 1.2-2.5</td>
</tr>
<tr>
<td>9</td>
<td>35 18-56</td>
<td>16 12-20</td>
<td>2.2 1.2-2.9</td>
</tr>
<tr>
<td>10</td>
<td>5.6 3.9-7.4</td>
<td>13 9.0-14</td>
<td>0.46 0.37-0.57</td>
</tr>
<tr>
<td>11</td>
<td>33 21-51</td>
<td>6.0 5.7-7.2</td>
<td>3.9 3.6-6.9</td>
</tr>
<tr>
<td>12</td>
<td>30 17-42</td>
<td>13 9.7-14</td>
<td>2.6 1.2-4.5</td>
</tr>
<tr>
<td>13</td>
<td>24 15-31</td>
<td>8.8 6.9-11</td>
<td>3.0 2.0-4.2</td>
</tr>
<tr>
<td>All</td>
<td>24 10-47</td>
<td>11 7.4-14</td>
<td>2.6 1.1-4.3</td>
</tr>
</tbody>
</table>
Figure 1.

A)

A. Urinary NGAL vs. urinary creatinine

B)

B. Urinary NGAL/creatinine ratio vs. urinary creatinine
Figure 2.

A)

A. Urinary NGAL vs. urinary creatinine

B)

B. Urinary NGAL/creatinine ratio vs. creatinine